Ultragenyx Pharmaceutical (RARE) Exchange Rate Effect (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Exchange Rate Effect of -$1.0 million for Q1 2026, down 200.0% year-over-year from $1.0 million in Q1 2025, and down 52.44% quarter-over-quarter from -$656000.0 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Exchange Rate Effect (2017 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 10 years of Exchange Rate Effect data on file, last reported at -$1.0 million in Q1 2026.
- Exchange Rate Effect for Q1 2026 came in at -$1.0 million, down 200.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 723.05% YoY), and the FY2025 annual result was $4.0 million, up 300.0% from the prior year.
- Exchange Rate Effect fell to -$1.0 million in Q1 2026 per RARE's latest filing, from -$656000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $3.4 million in Q2 2025 and troughed at -$1.9 million in Q4 2024.
- A 5-year average of -$4411.8 and a median of -$136000.0 in 2023 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect tumbled 421.8% in 2024, then soared 618.83% in 2025.
- A 5-year view of Exchange Rate Effect shows it stood at $1.4 million in 2022, then tumbled by 52.59% to $641000.0 in 2023, then tumbled by 403.9% to -$1.9 million in 2024, then jumped by 66.32% to -$656000.0 in 2025, then plunged by 52.44% to -$1.0 million in 2026.
- Business Quant data shows RARE's Exchange Rate Effect at -$1.0 million in Q1 2026, -$656000.0 in Q4 2025, and $294000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.60 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -2.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -40.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 8.68 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.00 Mn |
| Mar 31, 2026 | -1.00 Mn |
| Dec 31, 2025 | -656,000.00 |
| Dec 31, 2025 | -656,000.00 |
| Sep 30, 2025 | 294,000.00 |
| Sep 30, 2025 | 294,000.00 |
| Jun 30, 2025 | 3.36 Mn |
| Jun 30, 2025 | 3.36 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | -648,000.00 |
| Jun 30, 2024 | -648,000.00 |
| Mar 31, 2024 | -679,000.00 |
| Mar 31, 2024 | -679,000.00 |
| Dec 31, 2023 | 641,000.00 |
| Dec 31, 2023 | 641,000.00 |